Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial-Reference-Cited by-同舟云学术

Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial

Published:2018-04 Issue:4 Volume:29 Page:888-894
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Rugo H.S.,Diéras V.,Gelmon K.A.,Finn R.S.,Slamon D.J.,Martin M.,Neven P.,Shparyk Y.,Mori A.,Lu D.R.,Bhattacharyya H.,Bartlett C.H.u.a.n.g.,Iyer S.,Johnston S.,Ettl J.,Harbeck N.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/29/4/888/25082421/mdy012.pdf

Reference12 articles.

1. Addition of drug/s to a chemotherapy regimen for metastatic breast cancer Cochrane Database Syst Rev ; CD003368;Butters,2010

2. Combination versus sequential single-agent therapy in metastatic breast cancer;Miles;Oncologist,2002

3. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6;Toogood;J Med Chem,2005

4. Palbociclib and letrozole in advanced breast cancer;Finn;N Engl J Med,2016

5. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument;Brady;J Clin Oncol,1997

Cited by 116 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial;The Lancet Oncology;2024-09

2. Palbociclib: Randomized Studies and Real-world Evidence as the Basis for Therapeutic Planning in Metastatic Breast Cancer;Geburtshilfe und Frauenheilkunde;2024-09

3. Overall survival in first-line HR+/HER2- advanced breast cancer in the era of CDK4/6 inhibitors;Annals of Oncology;2024-08

4. Comparative cost-effectiveness analysis of CDK4/6 inhibitors in the first-line treatment of HR-positive and HER2-negative advanced breast cancer: a Markov's model-based evaluation;Frontiers in Oncology;2024-07-24

5. Quality-of-life survey of pancreatic cancer patients: a comparison between general public and physicians;Frontiers in Health Services;2024-07-12